Nonsteroidal anti-inflammatory drugs in the treatment of low back pain

Journal of Pain Research

Volumn 5, Issue , 2012, Pages 579-590

  Kuritzky, Louis ^a   Samraj, George P ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cyclo oxygenase 2; Low back pain; Non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CIMETIDINE; CYCLOOXYGENASE 2; DICLOFENAC; DICLOFENAC EPOLAMINE; IBUPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB;

ABDOMINAL PAIN; ADENOMATOUS POLYP; ANALGESIA; CHRONIC PAIN; COLON POLYP; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EVIDENCE BASED PRACTICE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION; HEALTH CARE COST; HUMAN; HYPERTENSION; LOW BACK PAIN; LOW DRUG DOSE; NAUSEA; PAIN; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 84874997460     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S6775     Document Type: Review

References (55)

1. Blount BW, Hart G, Ehreth JL. Description of the content of army family practice. J Am Board Fam Pract. 1993;6:143-152.
2. Koes BW, van Tulder MW, Ostelo R, Kim Burton A, Waddell G. Clinical guidelines for the management of low back pain in primary care: an international comparison. Spine (Phila Pa 1976). 2001;26(22): 2504-2513.
3. Koes BW, van Tulder M, Lin CW, Macedo LG, McAuley J, Maher C. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J. 2010;19: 2075-2094.
4. Guidelines for the management of acute nonspecific low back pain in primary care. Available from: http://www.backpaineurope.org/web/files/WG1_Guidelines.pdf. Accessed December 7, 2011.
5. Papageorgiou AC, Croft PR, Ferry S, et al. Estimating the prevalence of low back pain in the general population. Evidence from the South Manchester Back Pain Survey. Spine (Phila Pa 1976). 1995;20: 1889-1894.
6. Rathmell JP. A 50-year-old man with chronic LBP. JAMA. 2008;299: 2066-2077.
7. Grotle M, Brox J, Veierød M, et al. Clinical course and prognostic factors in acute low back pain: patients consulting primary care for the first time. Spine (Phila Pa 1976). 2005;30:976-982.
8. Elders L, Burdorf A. Prevalence, incidence, and recurrence of low back pain in scaffolders during a 3-year follow-up study. Spine (Phila Pa 1976). 2004;29:E101-E106.
9. Elders LAM, Van der Beek AJ, Burdorf A. Return to work after sickness absence due to back disorders: a systematic review on intervention strategies. Int Arch Occup Environ Health. 2000;73:339-348.
10. Tousignant M, Rossignol M, Goulet L, et al. Occupational disability to back pain: application of a theoretical model of work disability using prospective cohorts of manual workers. Am J Ind Med. 2000;37: 410-422.
11. Leboeuf-Yde C. Body weight and low back pain: a systematic literature review of 56journal articles reporting on 65 epidemiologic studies. Spine (Phila Pa 1976). 2000;25:226-237.
12. Jacobs J, Hammerman-Rozenberg R, Cohen A, et al. Chronic back pain among the elderly: prevalence, associations, and predictors. Spine (Phila Pa 1976). 2006;31:E203-E207.
13. Rubin DI. Epidemiology and risk factors for spine pain. Neurol Clin. 2007;25:353-371.
14. Ansani NT, Starz TW. Effective use of nonsteroidal anti-inflammatory drugs. The Female Patient. 2002;27:22-30.
15. Kuritzky L. Pain in the ambulatory setting: the role of nonsteroidal anti-inflammatory drugs. Primary Care Special Edition. 2003;7:9-12.
16. Kuritzky L. A practical approach to low back pain. Your Patient and Fitness. 1995;9:22-25.
17. Amadio P, Cummings DM, Amadio PB. NSAIDs revisited. Postgrad Med. 1997;101:257-271.
18. Huang J, Hunt RH. A clinician's view of strategies for preventing NSAID-induced gastrointestinal ulcers. Inflammopharmacology. 1996:4:17-30.
19. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1999;340: 1888-1899.
20. Abramson SB, Weaver AL. Current state of therapy for pain and inflammation. Arthritis Res Ther. 2005;7 Suppl 4:S1-S6.
21. Hooper L, Brown TJ, Elliott RA, Payne K, Roberts C, Symmons D. The effectiveness of fine strategies for the prevention of gastrointestinal toxicity induced by NSAIDs: systematic review. BMJ. 2004; 329:948.
22. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase 2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96:7563-7568.
23. Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2009;1:1-80.
24. Lister BJ, Poland M, DeLapp RE. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med. 1993;95:2S-9S.
25. Cannon GW, Breedveld FC. Efficacy of cyclooxygenase-2specific inhibitors. Am J Med. 2001;110:6S-12S.
26. Pollison R. Nonsteroidal anti-inflammatory drugs: practical and theoretical considerations in their selection. Am J Med. 1996;100:31S-36S.
27. Weaver A, Rubin B, Caldwell J, et al. Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee. Clin Ther. 1995;17:735-745.
28. Caldwell JR, Crain D, Hoffmeister RT, et al. Four-way, multicentre, crossover trial of ibuprofen, fenoprofen calcium, naproxen, and tomeltin sodium in osteoarthritis. Southern Med J. 1983;76:706-711.
29. Husby G, Holme I, Rugstad HE, et al. A double blind multicentre trial of piroxicam and naproxen in osteoarthritis. Clin Rheumatol. 1985;5: 84-91.
30. Brown BIL, Johnson JH, Hearron MS. Double-blind comparison of flurbiprofen and sulindac for the treatment of osteoarthritis. Am J Med. 1986;80 (Suppl 3A):112-117.
31. Kolodny AL. Two double-blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis. J Rheumatol. 1988;15:1205-1211.
32. Laine L. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage. 2003;25:32S-40S.
33. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475-481.
34. Weaver AL. Current and emerging treatments for mild/moderate acute ambulatory pain. Am J Ther. 2008;15:S12-S16.
35. Roth SH, Bennett RE, Mitchell CS, et al. Cimetidine therapy in NSAID drug gastropathy. Arch Intern Med. 1987;147:1798-1801.
36. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1995;123:241-249.
37. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs NSAIDs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
38. Juni P, Rutjes AWS, Dieppe PA. Are selective COX2inhibitors superior to traditional NSAIDs? Adequate analysis of the CLASS trial indicates that this may not be the case. BMJ. 2002;324:1287-1288.
39. DeMaria AN, Weir MR. Coxibs-beyond the GI tract: renal and cardiovascular issues. J Pain Symptom Manage. 2003;25:S41-S49.
40. Perazella MA. COX-2 inhibitors and the kidney. Hosp Pract (Minneap). 2001;36:43-46.
41. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events. JAMA. 2006;296:1619-1632.
42. Radford MG, Holley KE, Grande JP, et al. Reversible membranous nephropathy associated with the use of NSAIDs. JAMA. 1996;276: 466-469.
43. Clive DM, Stoff JS. Renal syndromes associated with NSAIDs. N Engl J Med. 1984;310:563-572.
44. Whelton A. Renal aspects of treatment with conventional NSAIDs versus cyclooxygenase-2-specific inhibitors. Am J Med. 2001; 110(Suppl 3A):33S-42S.
45. Solomon SD, McMurray JJV, Pfefer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.
46. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004; 351:1709-1711.
47. Hippisley-Cox J, Coupland C. Risk of MI in patient taking COX2inhibitors or conventional NSAIDs: population based nested case-control analysis. BMJ. 2005;330:1366-1369.
48. Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX2 specific inhibitors. Am J Manag Care. 2002;8:S401-S414.
49. McCarberg BH, Kuritzky L. Low back pain: Identification and management. J Musculoskelet Med. 2003;Suppl:S3-S21.
50. Cailliet R. Pain: mechanisms, assessment, and management. In: Soft Tissue Pain and Disability. 3rd ed. Philadelphia, PA: FA Davis Co; 1996.
51. Borenstein DG, Lacks S, Wiesel SW. Cyclobenzaprine and naproxen versus naproxen alone in the treatment of acute low back pain and muscle spasm. Clin Ther. 1990;12:125-131.
52. Moore RA, Tramer MR, Carroll D, et al. Quantitative systematic review of topically applied NSAIDs. BMJ. 1998;316:333-338.
53. Heyneman CA, Lawless-Liday C, Walll GC. Oral versus topical NSAIDs in rheumatic disease: a comparison. Drugs. 2000;60:555-574.
54. Ruoff G, Lema M. Strategies in pain management: new and potential indications for COX-2specific inhibitors. J Pain Symptom Manage. 2003;25:S21-S31.
55. Malmivaara A, Hakiinen U, Aro T, et al. The treatment of low back pain. N Engl J Med. 1995;332:351-355.